Kindred Biosciences, Inc. Form 3 December 11, 2013 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Sundlof Stephen	 Date of Event Requiring Statement (Month/Day/Year) 	3. Issuer Name and Ticker or Trading Symbol Kindred Biosciences, Inc. [KIN]					
(Last) (First) (Middle)	12/11/2013	4. Relationship Person(s) to Iss		5. If Amendment, Date Original Filed(Month/Day/Year)			
C/O KINDRED BIOSCIENCES INC., 1499 BAYSHORE HIGHWAY, SUITE 226 (Street) BURLINGAME, CA 94010		Director X Officer (give title below)	all applicable) 10% C Other) (specify below Vice President	wner 6. Individual or Joint/Group			
(City) (State) (Zip)	Table I - I	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security (Instr. 4)	2. Amount of Beneficially (Instr. 4)	Owned	Ownership	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Reminder: Report on a separate line for owned directly or indirectly.	each class of securities benefic	cially SE	EC 1473 (7-02)				
information con required to resp	spond to the collection of tained in this form are no ond unless the form disp MB control number.	t					

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security 2. Date Exercisable (Instr. 4) Expiration Date (Month/Day/Year)		Date	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	Derivative Security	Security: Direct (D)	

January 31,

2005

0.5

Expires:

response...

Estimated average burden hours per

Edgar Filing: Kindred Biosciences, Inc. - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Stock Option (right to buy) (1)	(2)	08/29/2023	Common Stock	50,000	\$ 1.37	D	Â
Stock Option (right to buy) $\frac{(1)}{2}$	(3)	11/09/2023	Common Stock	50,000	\$ 3.83	D	Â

Reporting Owners

Reporting Person

Reporting Owner Name / Address		Relationships					
		Director	10% Owner	Officer	Other		
Sundlof Stephen C/O KINDRED BIOSCIENCES, INC. 1499 BAYSHORE HIGHWAY, SUITE 226 BURLINGAME, CA 94010		Â	Â	Senior Vice President	Â		
Signatures							
/s/ Stephen Sundlof	12/11/2013						
<u>**</u> Signature of	Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Granted pursuant to the Issuer's 2012 Equity Incentive Plan
- (2) 12,500 of the shares subject to the option will vest on August 26, 2014, with the remaining shares vesting in equal monthly installments over the ensuing 36 months, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting dates.
- (3) 12,500 of the shares subject to the option will vest on November 9, 2014, with the remaining shares vesting in equal monthly installments over the ensuing 36 months, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting dates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.